UK biotech financing continues recovery trajectory on five-year Q2 high

Pharmaceutical Technology·July 20, 2026

AI Summary

UK biotech financing reached a five-year high in Q2, demonstrating continued recovery in the private investment sector. BIA CEO Chris Molloy emphasizes that sustained growth requires essential support from the UK public sector alongside private market investment.

From the source

While UK biotech financing recovery is present in the private markets, BIA CEO Chris Molloy notes that UK public sector backing is essential for sustained gr...

The full text couldn't be loaded here (the source may require a subscription).

View original at Pharmaceutical Technology

Was this useful?